These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23442069)

  • 21. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.
    Fyfe MC; McCormack JG; Overton HA; Procter MJ; Reynet C
    Expert Opin Drug Discov; 2008 Apr; 3(4):403-13. PubMed ID: 23489096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GPR120 agonism as a countermeasure against metabolic diseases.
    Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
    Drug Discov Today; 2014 May; 19(5):670-9. PubMed ID: 24315954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
    Matsumoto K; Yoshitomi T; Shimada T
    Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.
    Katz LB; Gambale JJ; Rothenberg PL; Vanapalli SR; Vaccaro N; Xi L; Sarich TC; Stein PP
    Diabetes Obes Metab; 2012 Aug; 14(8):709-16. PubMed ID: 22340428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The significance of GPR119 agonists as a future treatment for type 2 diabetes.
    Dhayal S; Morgan NG
    Drug News Perspect; 2010 Sep; 23(7):418-24. PubMed ID: 20862393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus.
    Manaithiya A; Alam O; Sharma V; Javed Naim M; Mittal S; Khan IA
    Bioorg Chem; 2021 Aug; 113():104998. PubMed ID: 34048996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
    Brocklehurst KJ; Broo A; Butlin RJ; Brown HS; Clarke DS; Davidsson Ö; Goldberg K; Groombridge SD; Kelly EE; Leach A; McKerrecher D; O'Donnell C; Poucher S; Schofield P; Scott JS; Teague J; Westgate L; Wood MJ
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7310-6. PubMed ID: 22061639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model.
    Park YH; Choi HH; Lee DH; Chung SY; Yang NY; Kim DH; Ju MK; Han TD; Nam SY; Kim KW
    Arch Pharm Res; 2017 Jun; 40(6):772-782. PubMed ID: 28593550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function.
    Odori S; Hosoda K; Tomita T; Fujikura J; Kusakabe T; Kawaguchi Y; Doi R; Takaori K; Ebihara K; Sakai Y; Uemoto S; Nakao K
    Metabolism; 2013 Jan; 62(1):70-8. PubMed ID: 22883930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.
    Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM
    J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural Insight on GPR119 Agonist as Potential Therapy for Type II Diabetes: A Comprehensive Review.
    Nema P; Asati V; Kendya P; Gupta T; Agarwal S; Kori S; Kashaw V; Iyer AK; Kashaw SK
    Mini Rev Med Chem; 2023; 23(21):2008-2040. PubMed ID: 36861804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
    Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
    J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges.
    Ritter K; Buning C; Halland N; Pöverlein C; Schwink L
    J Med Chem; 2016 Apr; 59(8):3579-92. PubMed ID: 26512410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists.
    Negoro K; Yonetoku Y; Misawa-Mukai H; Hamaguchi W; Maruyama T; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Sep; 20(17):5235-46. PubMed ID: 22836190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and biological evaluation of a 6-aminofuro[3,2-c]pyridin-3(2H)-one series of GPR 119 agonists.
    Sakairi M; Kogami M; Torii M; Kuno Y; Ohsawa Y; Makino M; Kataoka D; Okamoto R; Miyazawa T; Inoue M; Takahashi N; Harada S; Watanabe N
    Arzneimittelforschung; 2012 Nov; 62(11):537-44. PubMed ID: 22972470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.
    Scott JS; Bowker SS; Brocklehurst KJ; Brown HS; Clarke DS; Easter A; Ertan A; Goldberg K; Hudson JA; Kavanagh S; Laber D; Leach AG; MacFaul PA; Martin EA; McKerrecher D; Schofield P; Svensson PH; Teague J
    J Med Chem; 2014 Nov; 57(21):8984-98. PubMed ID: 25286150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained wash-resistant receptor activation responses of GPR119 agonists.
    Hothersall JD; Bussey CE; Brown AJ; Scott JS; Dale I; Rawlins P
    Eur J Pharmacol; 2015 Sep; 762():430-42. PubMed ID: 26101059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease.
    Smith AG; Muscat GE
    Int J Biochem Cell Biol; 2005 Oct; 37(10):2047-63. PubMed ID: 15922648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives.
    Quiñones M; Fernø J; Diéguez C; Nogueiras R; Al-Massadi O
    Expert Opin Drug Discov; 2019 May; 14(5):421-431. PubMed ID: 30821530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells.
    Sakamoto Y; Inoue H; Kawakami S; Miyawaki K; Miyamoto T; Mizuta K; Itakura M
    Biochem Biophys Res Commun; 2006 Dec; 351(2):474-80. PubMed ID: 17070774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.